- ￥190 - 2466
- Solarbio
- 北京
- IN4630
- 2025年07月21日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 保存条件：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 保质期：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 英文名：
NVP-ACC789
- 库存：
现询
- 供应商：
北京索莱宝科技有限公司
- CAS号：
300842-64-2
- 规格：
200mg/100mg/50mg/25mg/10mg/5mg/1mg
| 规格： | 200mg | 产品价格： | ￥2466.0 |
|---|---|---|---|
| 规格： | 100mg | 产品价格： | ￥1754.0 |
| 规格： | 50mg | 产品价格： | ￥1210.0 |
| 规格： | 25mg | 产品价格： | ￥850.0 |
| 规格： | 10mg | 产品价格： | ￥488.0 |
| 规格： | 5mg | 产品价格： | ￥300.0 |
| 规格： | 1mg | 产品价格： | ￥190.0 |
| 基本信息 | |
| CAS | No.300842-64-2 |
| 英文名称 | NVP-ACC789 |
| 分子式 | C21H17BrN4 |
| 分子量 | 405.29 |
| 溶解性 | Soluble in DMSO |
| 纯度 | ≥98% |
| 外观(性状) | Light yellow to yellow Solid |
| 储存条件 | Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| SMILES | CC1=C(C=C(C=C1)NC2=NN=C(C3=CC=CC=C32)CC4=CC=NC=C4)Br |
| InChIKey | GXWKSXUPEFVUOO-UHFFFAOYSA-N |
| InChI | InChI=1S/C21H17BrN4/c1-14-6-7-16(13-19(14)22)24-21-18-5-3-2-4-17(18)20(25-26-21)12-15-8-10-23-11-9-15/h2-11，13H，12H2，1H3，(H，24，26) |
| PubChem CID | 6918616 |
| 靶点 | VEGFR;PDGFR |
| 通路 | Angiogenesis; Protein Tyrosine Kinase/RTK |
| 背景说明 | NVP-ACC789是一种VEGFR-1，VEGFR-2，VEGFR-3 和 PDGFR-β 的抑制剂。 |
| 生物活性 | NVP-ACC789 is an inhibitor of human VEGFR-1， VEGFR-2 (mouse VEGFR-2)， VEGFR-3 and PDGFR-β with IC50s of 0.38， 0.02 (0.23)， 0.18， 1.4 μM， respectively.[1] |
| In Vitro | The enzymatic kinase assays demonstrate that NVP-ACC789 is an inhibitor of human VEGFR-1， VEGFR-2 (mouse VEGFR-2)， VEGFR-3 and PDGFR-β with IC50s of 0.38， 0.02 (0.23)， 0.18， 1.4 μM， respectively. In VEGF-treated cultures， addition of the VEGFR-2 inhibitor NVP-ACC789 reduces BME cell number to baseline levels from 1 μM. Likewise， bFGF-induced BME cell proliferation is reduced markedly by NVP-ACC789 from 1 to 10 μM， without however reaching basal levels. NVP-ACC789 is found to be a potent inhibitor of VEGF-induced HUVE cell proliferation with an IC50 of 1.6 nM. NVP-ACC789 also completely inhibits VEGF-induced BME and BAE cell invasion and VEGF-C-induced BAE cell invasion. The inhibition is dose-dependent in both cell types with a maximal effect from 1 μM[1]. |
| 细胞实验 | NVP-ACC789 which is given in daily oral doses for 6 days blocks VEGF-induced angiogenesis in a dose-dependent manner. NVP-ACC789 also inhibits the response to bFGF to some extent， but the dose-response curve is not linear for NVP-ACC789[1]. |
| 细胞实验 | HUVE cell proliferation is determined. Cells are seeded into 1.5% gelatin-coated 96-well plates (5×103 cells per well) and incubated in endothelial cell growth medium containing 5% fetal calf serum (FCS) for 24 h. The medium is replaced with essential basic medium (1.5% FCS)， and the cells are incubated for another 24 h. Essential basic medium is then replaced with fresh medium containing either 50 ng/mL VEGF or 0.5 ng/mL bFGF. NVP-ACC789 is added just before addition of growth factors. The cells are incubated for a further 24 h before adding the BrdU labeling solution. Twenty four hours later， the labeling solution is removed， the cells are fixed， and the incorporated BrdU is visualized with a peroxidase-labeled anti-BrdU antibody and TMB substrate[1]. |
| 动物实验 | Porous Teflon chambers (volume， 0.5 mL) filled with 0.8% w/v agar-containing heparin (20 U/mL) with or without VEGF (2 μg/mL) or bFGF (0.3 μg/mL) are implanted subcutaneously on the dorsal flank of female mice. The mice are treated with NVP-ACC789 (p.o. once daily) or vehicle (5% dimethyl sulfoxide， 1% Tween 80 in water) starting 1 day before implantation of the chamber and continuing for 5 days thereafter. At the end of the treatment period， the mice are killed， and the chambers are removed. The vascularized tissue growing around the chamber is removed carefully and weighed， and the blood content is assessed by measuring hemoglobin levels. The percentage inhibition of the angiogenic response (increase in tissue weight or total blood) is calculated. EC50 values are estimated from the dose response curves (% inhibition versus dose). Each experiment is performed with six animals per dose group and each dose is tested in at least two independent experiments[1]. |
| 激酶实验 | Human VEGFR-2-transfected CHO cells are seeded into 6-well plates and grown to about 80% confluency. NVP-ACC789 is added in serial dilutions and the cells incubated for 2 h at 37°C in medium without fetal calf serum (FCS). VEGF (20 ng/mL) is then added. After a 5-min incubation at 37°C， the cells are washed twice with ice-cold phosphate-buffered saline and lysed. Nuclei are removed by centrifugation for 10 min at 4°C. Protein concentrations of the lysates are determined[1]. |
| 数据来源文献 | [1]. Tille JC， et al. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basicfibroblast growth factor-induced angiogenesis in vivo and in vitro. J Pharmacol Exp Ther. 2001 Dec;299(3):1073-85. |
| 单位 | 瓶 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料
IN4630 NVP-ACC789 血管生成 索莱宝
￥190 - 2466
